Placebo of tolvaptan A placebo formulation containing no active pharmaceutical ingredient, used as a control comparator in clinical trials of tolvaptan.
Phase 3 pipeline
Aripiprazole (Fixed dose) · Psychiatry Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that stabilizes dopamine and serotonin neurotransmission in the brain.
Aripiprazole (Titrated dose) · Psychiatry/Neurology Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that modulates dopaminergic and serotonergic neurotransmission in the brain.
ASC-01 · Endocrinology / Musculoskeletal ASC-01 is a selective androgen receptor modulator (SARM) that activates androgen signaling in a tissue-selective manner.
Carteolol long-acting ophthalmic solution · Ophthalmology Carteolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.
CDP870 · Immunology CDP870 is a pegylated TNF-alpha inhibitor that binds and neutralizes tumor necrosis factor-alpha to reduce inflammatory responses.
Hyalein Mini Ophthalmic solution · Ophthalmology Hyalein Mini is a hyaluronic acid-based ophthalmic solution that lubricates and protects the ocular surface.
OPC-12759 · Psychiatry OPC-12759 is a selective dopamine D2 receptor antagonist.
OPC-12759 Ophthalmic suspension · Ophthalmology OPC-12759 is an ophthalmic suspension used to treat dry eye syndrome by increasing tear production.
OPC-14597 (Aripiprazole) · Psychiatry / Neurology Aripiprazole is a partial agonist at dopamine D2 and serotonin 5-HT1A receptors that stabilizes dopaminergic and serotonergic neurotransmission.
OPC-34712FUM/ Brexpiprazole fumarate · Psychiatry Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors while antagonizing serotonin 5-HT2A receptors.
OPC-41061 · Cardiovascular / Nephrology OPC-41061 is a vasopressin V2 receptor antagonist (vaptан) that blocks water reabsorption in the kidney collecting duct, promoting aquaresis and increasing serum sodium levels.
OPC-41061 （Tolvaptan) · Cardiovascular Tolvaptan is a selective, competitive antagonist of the vasopressin V2 receptor.
OPC-61815 injection · Oncology / Supportive Care OPC-61815 is a selective antagonist of the neurokinin-1 (NK1) receptor that reduces substance P signaling in the central nervous system.
OPC-6535 · Neurology / Pain OPC-6535 is a selective antagonist of the P2X7 receptor, which modulates purinergic signaling involved in inflammatory and immune responses.
Placebo of Aripiprazole This is a placebo control formulation with no active pharmacological mechanism.
Placebo of CDP870 This is a placebo control arm and contains no active pharmaceutical ingredient.
Placebo of SPM 962 Placebos do not have an active pharmacological mechanism; they are used as controls in clinical trials.
SPM 962 · Autoimmune diseases SPM 962 is a selective, high-affinity, and orally bioavailable small molecule inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1).
TEV-48125 · Cardiovascular TEV-48125 is a selective, reversible inhibitor of the sodium-activated potassium channel Nav1.5.
Tolvaptan Oral Tablet · Nephrology / Endocrinology Tolvaptan is a selective vasopressin V2-receptor antagonist that blocks water reabsorption in the kidney's collecting duct, promoting aquaresis (water excretion) without significant electrolyte loss.
Phase 2 pipeline
13C-uracil · Oncology 13C-uracil is a radiolabeled analog of the pyrimidine nucleoside uracil, used for PET imaging of pyrimidine metabolism.